Photo taken from Andy Hahn/X
Oct 7, 2024, 07:05
Andrew W Hahn: How effective and tolerable is Belzutifan in treating Sporadic Metastatic Clear Cell Renal Cell Carcinoma
, Genitourinary Medical Oncologist, MD Anderson Cancer Center, shared a post on X:
“ Check out our single-center, real-world experience with belzutifan in 22 patients with metastatic Clear Cell Renal Cell Carcinoma who were treated prior to the FDA approval. Led by our outstanding pharmacist, Emily Wang.
Belzutifan had meaningful activity in this heavily pre-treated cohort with ORR of 36.4%, median PFS of 8.5 months, and median OS of 14.7 months. We provide a detailed summary of the responders to belzutifan and our experience managing AEs of hypoxia and anemia.“
Source: Andy Hahn/X
Amado J Zurita
Amishi Y Shah
Andrew C Johns
Andrew W Hahn
Andy Hahn
belzutifan
cancer
cancer awareness
cancer care
Emily Wang
Eric Jonasch
Eric S Rupe
fight against cancer
Global fight against cancer
Jianjun Gao
Matthew T Campbell
Nizar M. Tannir
OncoDaily
Oncology
Pavlos Msaouel
RENAL CARCINOMA
Sagar S Mukhida
Sangeeta Goswami
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 7, 2024, 06:54
Oct 7, 2024, 06:50
Oct 7, 2024, 06:49
Oct 7, 2024, 06:44